These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25484042)

  • 1. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
    Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
    MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
    Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
    MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
    Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
    Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
    Nagy CF; Leach TS; Hoffman JH; Czech A; Carpenter SE; Guttendorf R
    Clin Ther; 2016 Sep; 38(9):2083-2097.e7. PubMed ID: 27568215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
    Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.
    Hambuchen MD; Rüedi-Bettschen D; Williams DK; Hendrickson H; Owens SM
    Vaccine; 2014 Oct; 32(47):6213-9. PubMed ID: 25252196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
    Li X; Li B; Wang M; Fang M; Lou J; Liu J; Chen H; Ding Y
    BioDrugs; 2024 Mar; 38(2):313-321. PubMed ID: 38148466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers.
    Allison DE; Gourlay SG; Koren E; Miller RM; Fox JA
    BioDrugs; 2002; 16(1):63-70. PubMed ID: 11968154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
    Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X
    J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau.
    Luca W; Foster K; McClure K; Ahlijanian MK; Jefson M
    J Prev Alzheimers Dis; 2024; 11(2):366-374. PubMed ID: 38374743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
    Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.
    White B; Leon F; White W; Robbie G
    Clin Ther; 2009 Apr; 31(4):728-40. PubMed ID: 19446146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
    Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
    Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers.
    Mallory RM; Ali SO; Takas T; Kankam M; Dubovsky F; Tseng L
    Biologicals; 2017 Nov; 50():81-86. PubMed ID: 28844541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Phase 1 Study to Assess the Safety and Pharmacokinetics of the Subcutaneously Injected Anti-LIGHT Antibody, SAR252067.
    Zhang M; Perrin L; Pardo P
    Clin Pharmacol Drug Dev; 2017 May; 6(3):292-301. PubMed ID: 27545119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.
    Kretsos K; Golor G; Jullion A; Hickling M; McCabe S; Shaw S; Jose J; Oliver R
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):388-95. PubMed ID: 27129012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
    Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.